Core F: Biomarker Core

项目摘要/摘要-生物标记物核心 Biomarker Core(BC)将提供整个亚利桑那州ADRC的通道，以促进脑成像、液体和 可穿戴/数字生物标记器的专业知识、资源、数据和样本，供我们的中心和 支持NIA ADRC计划目标的补充性附属队列。亚利桑那州的ADRC有一个主要的 专题重点是推动在临床前诊断中使用基于血液的生物标记物的努力 阿尔茨海默病的研究和预防。该委员会将促进这一主题的重点，通过支持ADRC的研究人员 努力：1)进一步阐明与临床前AD相关的认知和生物学变化；2)验证和 阐明新的脑成像、脑脊液和基于血液的生物标记物在早期发现和跟踪脑血管疾病中的作用 并评估可穿戴/数字技术作为行为AD生物标志物的潜力；3)告知 支持不同AD风险水平的个体的预防试验的设计、终点和统计能力 我们的目标是找到有效的AD预防疗法；以及4)为亚利桑那州提供宝贵的共享资源 ADRC研究人员，NIA ADRC全国计划，以及世界各地研究AD和 相关的障碍。为了实现这些目标，BC将支持标准化的采购、处理和 淀粉样蛋白PET、tau PET和MRI的分析；标准化收集、制备、储存和分析 血液、脑脊液和DNA样本；以及可穿戴/数字行为的采集、处理和分析 临床特征良好的ADRC参与者中的生物标记物，其中许多人也同意使用大脑 捐款。卑诗省将与NCRAD在血液加工和银行方面保持牢固的关系 脑脊液样本，并将全力支持NIA Scan倡议，以共享和存档ADRC BC 使用NACC进行神经成像扫描。BC将提供专业知识和支持，帮助ADRC研究人员充分 利用核心资源，并将与亚利桑那州ADRC的每个核心以及 以及亚利桑那州以外的地区，以推进与AD相关的研究。委员会将处理以下具体目标：1) 提供对淀粉样蛋白和tau PET、MRI扫描、脑脊液和血液样本以及可穿戴/数字活动数据的访问 在亚利桑那州ADRC；2)为研究提供神经成像数据、液体样本和 来自临床特征良好的ADRC参与者的生物标志物和可穿戴/数字活动数据；3)至 支持开发、评估和实施基于血液的生物标志物，用于早期检测和 跟踪AD风险和病理；4)为脑图像处理提供专业知识和支持资源 和用于AD相关研究的分析；以及5)通过密切合作促进合作研究 每个亚利桑那州ADRC核心，以及亚利桑那州内外这些核心资源的用户。

PROJECT SUMMARY/ABSTRACT - BIOMARKER CORE The Biomarker Core (BC) will provide access across the Arizona ADRC to advance brain imaging, fluid, and wearable/digital biomarker expertise, resources, data, and specimens for application with our center and complementary affiliated cohorts to support NIA ADRC program goals. The Arizona ADRC has a major thematic focus on advancing efforts in the use of blood-based biomarkers (BBBs) in the diagnosis, preclinical study and prevention of AD. The BC will facilitate this thematic focus by supporting ADRC researchers in their efforts to: 1) further clarify the cognitive and biological changes associated with preclinical AD; 2) validate and clarify the role of new brain imaging, CSF, and blood-based biomarkers in the early detection and tracking of AD and to evaluate the potential of wearable/digital technologies as behavioral AD biomarkers; 3) inform the design, endpoints, and statistical power of prevention trials in individuals at different levels of AD risk to support our goal of finding effective AD prevention therapies; and 4) provide a valuable shared resource for Arizona ADRC researchers, the NIA ADRC program nationally, and researchers around the world studying AD and related disorders. To achieve these goals, the BC will support the standardized acquisition, processing, and analysis of amyloid PET, tau PET, and MRI; the standardized collection, preparation, storage, and analysis of blood, CSF, and DNA samples; and the acquisition, processing, and analysis of wearable/digital behavioral biomarkers in clinically well-characterized ADRC participants, many of whom have also agreed to brain donation. The BC will maintain a strong relationship with NCRAD for the processing and banking of blood and CSF samples and will fully support the NIA SCAN initiative for the sharing and archiving of ADRC BC neuroimaging scans with NACC. The BC will provide expertise and support to help ADRC researchers fully utilize the core resources and will work with each of the Arizona ADRC Cores, as well as investigators within and outside Arizona, to advance AD-related research. The BC will address the following specific aims: 1) to provide access to amyloid and tau PET, MRI scans, CSF and blood samples, and wearable/digital activity data across the Arizona ADRC; 2) to make available for research neuroimaging data, fluid specimens and biomarkers, and wearable/digital activity data from clinically well-characterized ADRC participants; 3) to support the development, evaluation, and implementation of blood-based biomarkers for early detection and tracking of AD risk and pathology; 4) to provide a resource of expertise and support for brain image processing and analysis for use in AD-related research studies; and 5) to foster collaborative research by working closely with each of the Arizona ADRC Cores, as well as users of these core resources inside and outside Arizona.